drug · small molecule
giredestrant
pre_registrationupdated 6mo agoby Genentech Inc🔗 ChEMBL
community read0 votes
🐶 often sniffed alongside
top 4Small molecule drug with a maximum clinical stage of Phase 3 (across all indications), with 3 investigational indications.
indications
indications
Breast Cancer
targets
Estrogen receptor
all catalysts(0)
nothing on the calendar yet
Trials studying giredestrant
- phase3A Study Evaluating Adherence, Tolerability, and Patient Reported Outcomes of Giredestrant in Participants With ER+/HER2- Early Breast Cancer Who Are Intolerant to Adjuvant Aromatase Inhibitor Therapy (novERA Breast Cancer)
- phase3A Study of a Medicine Called Atirmociclib in Combination With Giredestrant in Adult Participants With ER-positive, HER2-negative Early-stage Breast Cancer
- phase2Study to Test the Safety and Tolerability of PF-07220060 in Participants With Advance Solid Tumors
- phase3A Rollover Study for Participants Previously Enrolled in a Genentech and/or F. Hoffman-La Roche Sponsored Study
- phase1A Study to Evaluate the Effects of GDC-4198 in Combination With Letrozole, Fulvestrant, or Giredestrant in Participants With Locally Advanced or Metastatic Hormone Receptor-Positive, HER2-Negatve Breast Cancer
- phase3A Study to Learn How Well Participants With a Specific Type of Early Breast Cancer (ER-Positive, HER2-Negative) Tolerate and Stay on Treatment With Giredestrant and How They Feel During Treatment
- phase2A Study to Test Inavolisib Treatments in Participants With Early-Stage, PIK3CA-Mutated Breast Cancer
- phase2A Study to Evaluate the Effect of GDC-4198 Alone and in Combination With Giredestrant Versus Abemaciclib and Giredestrant in Participants With Locally Advanced or Metastatic Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor-Negative (HER2-) Breast Cancer
News(10)
- STAT+: Pharmalittle: We’re reading about a Roche breast cancer pill, obesity drugs in children, and moreThe FDA approved a breast cancer drug from Roche, teeing up the launch of what the company has said could become its top-selling productstat · 6h ago
- Roche enters the SERD market with FDA approval in late-stage breast cancerRoche’s big-hope breast cancer pill giredestrant was in an odd situation in that it was awaiting two different FDA approval decisions. Also oddly, the second one came first. The drug wasendpoints · 8h ago
- STAT+: FDA approves new breast cancer drug, providing new option for some patients, boost for RocheThe FDA approved a new breast cancer drug from Roche, teeing up the launch of a medicine the company has said could become its top-selling product ever.stat · 23h ago
- Roche’s changing plans show how MFN is complicating European drug launchesRoche will seek European approval for its promising new breast cancer pill giredestrant later than it once expected, highlighting how US drug pricing pressure may be affecting pharmaceutical compan…endpoints · 22d ago
- Roche says it will help patients who are 'anxiously awaiting' its new breast cancer drugRoche is gearing up for a major launch with its breast cancer pill giredestrant, and according to Teresa Graham, head of the company’s pharma unit, patients are clamoring to get hold of the drug. G…endpoints · 26d ago
- Roche affirms sales outlook amid doubts about its futureLower-than-expected sales of Xolair stood out as the Swiss drugmaker readies for an onslaught of generic competition for top products.biopharma_dive · 26d ago
- ‘We’re so close to the tech companies’: Genentech CEO talks Fierce through vision for the futureWhen recombinant DNA pioneer Herbert Boyer, Ph.D., first got a call from venture capitalist Robert Swanson about starting a company, the savvy scientist wasn’t sure a meeting would be worth his time.fiercebiotech · 1mo ago
- Roche, Ionis RNA drug scores in kidney disease studyThe results position Roche to bring a new kind of medicine to market for IgA nephropathy, a disease that’s drawn considerable attention of late from drugmakers.biopharma_dive · 1mo ago
- AstraZeneca’s newly approved pill fails frontline breast cancer studyEtcamah is the second oral “SERD” to recently fall short in first-line breast cancer, following a similar setback from Roche earlier this year.biopharma_dive · 2mo ago
- FDA approves AstraZeneca’s Etcamah, opening ctDNA-guided treatment paradigm in breast cancerIn a rare divergence from its own expert panel, the FDA has granted accelerated approval to AstraZeneca’s camizestrant, turning a contentious regulatory review into a landmark win that opens a new…fiercebiotech · 2mo ago
Data sources
last refreshed 7h ago
Found something off?
comments(0)
5-min edit window · permanent after that